Performance fatigability in adults with spinal muscular atrophy treated long‐term with nusinersen
This study demonstrates the presence of PF as an independent component of motor impairment and as a potential therapeutic target in our cohort of adult ambulatory pwSMA. Furthermore, the observations in our cohort suggest that nusinersen may have a beneficial effect on PF.
Authors
- Christoph Kleinschnitz (ORCID: https://orcid.org/0000-0002-1650-8875)
- Benjamin Stolte (ORCID: https://orcid.org/0000-0002-2774-067X)
- Tim Hagenacker (ORCID: https://orcid.org/0000-0002-3631-3450)
- Cornelius Deuschl (ORCID: https://orcid.org/0000-0001-9262-7289)
- Teresa Kruse (ORCID: https://orcid.org/0000-0002-3431-7749)
- Otgonzul von Velsen (ORCID: https://orcid.org/0000-0001-8841-2509)
- Melina Schlag
- Jaqueline Lipka
- Svenja Neuhoff (ORCID: https://orcid.org/0000-0003-0678-0100)
Institutions
- University of Cologne (DE)
- Institut für Medizinische Informatik, Biometrie und Epidemiologie (DE)
- Essen University Hospital (DE)
- University Hospital Cologne (DE)
Publication Details
- Journal
- Muscle & Nerve
- Published
- 2024-10-03
- DOI
- https://doi.org/10.1002/mus.28269
- Citations
- 5
- Primary Topic
- Neurogenetic and Muscular Disorders Research
- Type
- article
- Field-Weighted Citation Impact
- 2.19
Funders
- Amgen
- Pfizer
- Sanofi
- Biogen
- Teva Pharmaceutical Industries
- Alexion Pharmaceuticals
- CSL Behring
- Ablynx
- Mylan
- Daiichi-Sankyo
- Eisai
- EVER Neuro Pharma
- MedDay Pharmaceuticals
- Sanofi Genzyme
- Bayer Vital